185 related articles for article (PubMed ID: 16183931)
21. Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo.
Strieth S; Eichhorn ME; Sutter A; Jonczyk A; Berghaus A; Dellian M
Int J Cancer; 2006 Jul; 119(2):423-31. PubMed ID: 16477628
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors.
d'Assignies G; Couvelard A; Bahrami S; Vullierme MP; Hammel P; Hentic O; Sauvanet A; Bedossa P; Ruszniewski P; Vilgrain V
Radiology; 2009 Feb; 250(2):407-16. PubMed ID: 19095784
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Peterson AC; Swiger S; Stadler WM; Medved M; Karczmar G; Gajewski TF
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4048-54. PubMed ID: 15217937
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor.
Deng G; Zhao DL; Li GC; Yu H; Teng GJ
Cardiovasc Intervent Radiol; 2011 Aug; 34(4):824-32. PubMed ID: 21671151
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
26. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
27. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856
[TBL] [Abstract][Full Text] [Related]
29. Quantitative contrast enhanced ultrasound and CT assessment of tumor response to antiangiogenic therapy in rats.
Pollard RE; Broumas AR; Wisner ER; Vekich SV; Ferrara KW
Ultrasound Med Biol; 2007 Feb; 33(2):235-45. PubMed ID: 17306694
[TBL] [Abstract][Full Text] [Related]
30. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels.
Osusky KL; Hallahan DE; Fu A; Ye F; Shyr Y; Geng L
Angiogenesis; 2004; 7(3):225-33. PubMed ID: 15609077
[TBL] [Abstract][Full Text] [Related]
31. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G
Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193
[TBL] [Abstract][Full Text] [Related]
32. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.
Kambadakone A; Yoon SS; Kim TM; Karl DL; Duda DG; DeLaney TF; Sahani DV
AJR Am J Roentgenol; 2015 Jan; 204(1):W11-8. PubMed ID: 25539263
[TBL] [Abstract][Full Text] [Related]
33. CT perfusion for determination of pharmacologically mediated blood flow changes in an animal tumor model.
Hakimé A; Peddi H; Hines-Peralta AU; Wilcox CJ; Kruskal J; Lin S; de Baere T; Raptopoulos VD; Goldberg SN
Radiology; 2007 Jun; 243(3):712-9. PubMed ID: 17517930
[TBL] [Abstract][Full Text] [Related]
34. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
35. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.
Sabir A; Schor-Bardach R; Wilcox CJ; Rahmanuddin S; Atkins MB; Kruskal JB; Signoretti S; Raptopoulos VD; Goldberg SN
AJR Am J Roentgenol; 2008 Jul; 191(1):133-9. PubMed ID: 18562736
[TBL] [Abstract][Full Text] [Related]
36. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
Bergers G; Song S; Meyer-Morse N; Bergsland E; Hanahan D
J Clin Invest; 2003 May; 111(9):1287-95. PubMed ID: 12727920
[TBL] [Abstract][Full Text] [Related]
37. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Huss WJ; Barrios RJ; Greenberg NM
Mol Cancer Ther; 2003 Jul; 2(7):611-6. PubMed ID: 12883033
[TBL] [Abstract][Full Text] [Related]
38. Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study.
Pahernik S; Harris AG; Schmitt-Sody M; Krasnici S; Goetz AE; Dellian M; Messmer K
Br J Cancer; 2002 May; 86(10):1622-7. PubMed ID: 12085213
[TBL] [Abstract][Full Text] [Related]
39. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
